Modality
Small Molecule
MOA
SOS1i
Target
FLT3
Pathway
Angiogenesis
BCCPsoriasis
Development Pipeline
Preclinical
Apr 2020
→ Jun 2029
PreclinicalCurrent
NCT07501959
374 pts·Psoriasis
2023-05→2029-06·Active
NCT06304414
2,507 pts·BCC
2020-04→TBD·Not yet recruiting
2,881 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-173.2y awayInterim· Psoriasis
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2029-06-17 · 3.2y away
Psoriasis
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07501959 | Preclinical | Psoriasis | Active | 374 | BodyWt |
| NCT06304414 | Preclinical | BCC | Not yet recr... | 2507 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |